Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Description

The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

Conditions

End Stage Renal Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Condition
End Stage Renal Disease
Intervention / Treatment

-

Contacts and Locations

San Antonio

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or Female
  • 2. Age 18-64 years
  • 3. Receiving 3 x weekly in clinic hemodialysis for at least 6 months
  • 1. Hypersensitivity to amino acid(s) and/or any excipient
  • 2. Clinical documentation of COVID-19
  • 3. Concomitant intake of amino acids supplements
  • 4. Current use or abuse of alcohol, marijuana, narcotic, or other substances
  • 5. Heart failure receiving active management
  • 6. Malignant cancer receiving anticancer therapy
  • 7. Diagnosis of major depressive disorder receiving antidepressants
  • 8. Diagnosis of chronic liver disease
  • 9. Cerebrovascular disease with sequelae
  • 10. Upper limb amputation, osteoarthritis, or degenerative diseases of fingers, carpel tunnel syndrome in the non-fistula or graft hand preventing completion of hand grip strength test.

Ages Eligible for Study

18 Years to 64 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Subrata Debnath, PhD, PRINCIPAL_INVESTIGATOR, University of Texas Health Science Center San Antonio

Study Record Dates

2026-03